

# Aimã©e R Kreimer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5302365/publications.pdf>

Version: 2024-02-01

66  
papers

7,129  
citations

109137

35  
h-index

106150

65  
g-index

66  
all docs

66  
docs citations

66  
times ranked

7760  
citing authors

#	ARTICLE	IF	CITATIONS
1	Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 467-475.	1.1	1,819
2	The Case for Conducting a Randomized Clinical Trial to Assess the Efficacy of a Single Dose of Prophylactic HPV Vaccines Among Adolescents. <i>Journal of the National Cancer Institute</i> , 2015, 107, 1-4.	3.0	406
3	Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica. <i>PLoS ONE</i> , 2013, 8, e68329.	1.1	387
4	Oral Human Papillomavirus Infection in Adults Is Associated with Sexual Behavior and HIV Serostatus. <i>Journal of Infectious Diseases</i> , 2004, 189, 686-698.	1.9	329
5	Evaluation of Human Papillomavirus Antibodies and Risk of Subsequent Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 2708-2715.	0.8	280
6	Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1444-1451.	3.0	274
7	Oral Human Papillomavirus in Healthy Individuals: A Systematic Review of the Literature. <i>Sexually Transmitted Diseases</i> , 2010, 37, 386-391.	0.8	249
8	Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. <i>Lancet Oncology</i> , The, 2015, 16, 775-786.	5.1	247
9	Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. <i>Lancet</i> , The, 2013, 382, 877-887.	6.3	239
10	HPV16 E7 Genetic Conservation Is Critical to Carcinogenesis. <i>Cell</i> , 2017, 170, 1164-1174.e6.	13.5	221
11	Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial. <i>Cancer Prevention Research</i> , 2013, 6, 1242-1250.	0.7	185
12	The Epidemiology of Oral HPV Infection among a Multinational Sample of Healthy Men. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 172-182.	1.1	169
13	Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. <i>Lancet Oncology</i> , The, 2011, 12, 862-870.	5.1	168
14	Prevention of Persistent Human Papillomavirus Infection by an HPV16/18 Vaccine: A Community-Based Randomized Clinical Trial in Guanacaste, Costa Rica. <i>Cancer Discovery</i> , 2011, 1, 408-419.	7.7	143
15	Associations of Oral $\hat{1}_{\pm}$ , $\hat{1}_{2-}$ , and $\hat{1}_{3}$ -Human Papillomavirus Types With Risk of Incident Head and Neck Cancer. <i>JAMA Oncology</i> , 2016, 2, 599.	3.4	135
16	Anal Cancer Incidence in the United States, 1977â€“2011: Distinct Patterns by Histology and Behavior. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1548-1556.	1.1	131
17	Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 215, 212.e1-212.e15.	0.7	108
18	Evidence for single-dose protection by the bivalent HPV vaccineâ€”Review of the Costa Rica HPV vaccine trial and future research studies. <i>Vaccine</i> , 2018, 36, 4774-4782.	1.7	103

#	ARTICLE	IF	CITATIONS
19	Human Papillomavirus Testing Following Loop Electrosurgical Excision Procedure Identifies Women at Risk for Posttreatment Cervical Intraepithelial Neoplasia Grade 2 or 3 Disease. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 908-914.	1.1	98
20	Natural Acquired Immunity Against Subsequent Genital Human Papillomavirus Infection: A Systematic Review and Meta-analysis. <i>Journal of Infectious Diseases</i> , 2016, 213, 1444-1454.	1.9	96
21	Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv302.	3.0	92
22	Kinetics of the Human Papillomavirus Type 16 E6 Antibody Response Prior to Oropharyngeal Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	77
23	Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial. <i>Journal of the National Cancer Institute</i> , 2018, 110, 205-212.	3.0	71
24	Human papillomavirus 16 <sc>E</sc>6 antibodies are sensitive for human papillomavirusâ€driven oropharyngeal cancer and are associated with recurrence. <i>Cancer</i> , 2017, 123, 4382-4390.	2.0	67
25	Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: A systematic review of evidence from clinical trials. <i>Vaccine</i> , 2020, 38, 1302-1314.	1.7	61
26	Gender Differences in Sexual Biomarkers and Behaviors Associated With Human Papillomavirus-16, âˆ²18, and âˆ²33 Seroprevalence. <i>Sexually Transmitted Diseases</i> , 2004, 31, 247-256.	0.8	60
27	HPV16 semiquantitative viral load and serologic biomarkers in oral and oropharyngeal squamous cell carcinomas. <i>International Journal of Cancer</i> , 2005, 115, 329-332.	2.3	59
28	Long-term Persistence of Oral Human Papillomavirus Type 16: The HPV Infection in Men (HIM) Study. <i>Cancer Prevention Research</i> , 2015, 8, 190-196.	0.7	55
29	Human Papillomavirus 16 E6 Antibodies in Individuals without Diagnosed Cancer: A Pooled Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 683-689.	1.1	54
30	Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial. <i>Lancet Oncology</i> , The, 2020, 21, 1643-1652.	5.1	54
31	Screening for human papillomavirusâ€driven oropharyngeal cancer: Considerations for feasibility and strategies for research. <i>Cancer</i> , 2018, 124, 1859-1866.	2.0	48
32	Prospects for prevention of HPV-driven oropharynx cancer. <i>Oral Oncology</i> , 2014, 50, 555-559.	0.8	46
33	Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw300.	3.0	43
34	Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: The CVT Trial. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1030-1037.	3.0	42
35	Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI. <i>Oral Oncology</i> , 2020, 108, 104736.	0.8	40
36	HPV-associated Oropharyngeal Cancersâ€Are They Preventable?. <i>Cancer Prevention Research</i> , 2011, 4, 1346-1349.	0.7	37

#	ARTICLE	IF	CITATIONS
37	Viral Determinants of Human Papillomavirus Persistence following Loop Electrical Excision Procedure Treatment for Cervical Intraepithelial Neoplasia Grade 2 or 3. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 11-16.	1.1	35
38	Anthropometry and head and neck cancer: a pooled analysis of cohort data. <i>International Journal of Epidemiology</i> , 2015, 44, 673-681.	0.9	32
39	Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial. <i>BMJ</i> , 2015, 351, h4358.	3.0	32
40	Characterization of human papillomavirus antibodies in individuals with head and neck cancer. <i>Cancer Epidemiology</i> , 2016, 42, 46-52.	0.8	32
41	Long-term risk of recurrent cervical human papillomavirus infection and precancer and cancer following excisional treatment. <i>International Journal of Cancer</i> , 2012, 131, 211-218.	2.3	29
42	Performance of Self-Collected Cervical Samples in Screening for Future Precancer Using Human Papillomavirus DNA Testing. <i>Journal of the National Cancer Institute</i> , 2014, 107, dju400-dju400.	3.0	24
43	Human Papillomavirus (HPV) L1 Serum Antibodies and the Risk of Subsequent Oral HPV Acquisition in Men: The HIM Study. <i>Journal of Infectious Diseases</i> , 2016, 214, 45-48.	1.9	21
44	Eurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines. <i>International Journal of Cancer</i> , 2016, 139, 510-517.	2.3	19
45	An Examination of HPV16 Natural Immunity in Men Who Have Sex with Men (MSM) in the HPV in Men (HIM) Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 496-502.	1.1	19
46	Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials. <i>Journal of the National Cancer Institute</i> , 2020, 112, 818-828.	3.0	19
47	Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica. <i>Vaccine</i> , 2015, 33, 2141-2151.	1.7	17
48	HPV vaccination initiation after the routine-recommended ages of 11-12 in the United States. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2016, 2, 11-16.	4.5	17
49	Evaluation of TypeSeq, a Novel High-Throughput, Low-Cost, Next-Generation Sequencing-Based Assay for Detection of 51 Human Papillomavirus Genotypes. <i>Journal of Infectious Diseases</i> , 2019, 220, 1609-1619.	1.9	17
50	Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: The Costa Rica ESCUDDO trial. <i>Vaccine</i> , 2022, 40, 76-88.	1.7	15
51	Absolute Risk of Oropharyngeal Cancer After an HPV16-E6 Serology Test and Potential Implications for Screening: Results From the Human Papillomavirus Cancer Cohort Consortium. <i>Journal of Clinical Oncology</i> , 2022, 40, 3613-3622.	0.8	14
52	Oral Sexual Behaviors and the Prevalence of Oral Human Papillomavirus Infection. <i>Journal of Infectious Diseases</i> , 2009, 199, 1253-1254.	1.9	13
53	Design and statistical considerations for studies evaluating the efficacy of a single dose of the human papillomavirus (HPV) vaccine. <i>Contemporary Clinical Trials</i> , 2018, 68, 35-44.	0.8	12
54	Evaluation of serological assays to monitor antibody responses to single-dose HPV vaccines. <i>Vaccine</i> , 2020, 38, 5997-6006.	1.7	11

#	ARTICLE	IF	CITATIONS
55	Trends in cervical cancer incidence in younger US women from 2000 to 2013. <i>Gynecologic Oncology</i> , 2017, 144, 391-395.	0.6	10
56	HPV16 E6 seropositivity among cancer-free men with oral, anal or genital HPV16 infection. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2016, 2, 141-144.	4.5	9
57	The Beginning of the End: Vaccine Prevention of HPV-Driven Cancers. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv128-djv128.	3.0	7
58	Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study. <i>Journal of Infectious Diseases</i> , 2021, 223, 1576-1581.	1.9	7
59	Prioritisation of the human papillomavirus vaccine in a time of constrained supply. <i>The Lancet Child and Adolescent Health</i> , 2020, 4, 349-351.	2.7	6
60	Association Between Common Vaginal Infections and Cervical Non-Human Papillomavirus (HPV) 16/18 Infection in HPV-Vaccinated Women. <i>Journal of Infectious Diseases</i> , 2021, 223, 445-451.	1.9	5
61	Different human papillomavirus types share early natural history transitions in immunocompetent women. <i>International Journal of Cancer</i> , 2022, 151, 920-929.	2.3	5
62	Risk Factors for Non-Human Papillomavirus (HPV) Type 16/18 Cervical Infections and Associated Lesions Among HPV DNA-Negative Women Vaccinated Against HPV-16/18 in the Costa Rica Vaccine Trial. <i>Journal of Infectious Diseases</i> , 2021, 224, 503-516.	1.9	4
63	Real-World HPV Vaccine Effectiveness Studies: Guideposts for Interpretation of Current and Future Studies. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1270-1271.	3.0	2
64	Nasopharyngeal carcinoma patients from Norway show elevated Epstein-Barr virus IgA and IgG antibodies prior to diagnosis. <i>Cancer Epidemiology</i> , 2022, 77, 102117.	0.8	2
65	HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial. <i>Npj Vaccines</i> , 2022, 7, 40.	2.9	1
66	Fewer than three doses of HPV vaccine – Authors' reply. <i>Lancet Oncology</i> , The, 2015, 16, e424-e425.	5.1	0